Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. 4 key findings →
Design: post-hoc analysis Participants: 10,000 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
33,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. 4 key findings →
Design: post-hoc analysis Participants: 10,000 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is the most common cause of dementia in older people. 4 key findings →
Design: meta-analysis Participants: 8,257 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Vascular cognitive impairment (VCI) describes a broad spectrum of cognitive impairments caused by cerebrovascular disease, ranging from mild cognitive impairment to dementia. 4 key findings →
Design: meta-analysis Participants: 2,193 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Selection criteria Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia. 5 key findings →
Design: meta-analysis Participants: 692 Evidence: high
Full summary, score breakdown and related studies → Original source
Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). 4 key findings →
Participants: 1,236 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. 4 key findings →
Participants: 3,232 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. 4 key findings →
Participants: 6,805 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Main results Effect of memantine in patients with moderate to severe Alzheimer's disease: analysis of the change from baseline at 28 weeks gave statistically significant results in favour of memantine for 20 mg/day on cognition (MD: 6.1. 95% CI 2.99 to 9.21, P=0.0001) activities of daily living (MD 2.10, 95% CI 0.46 to 3.74, p=0.01) and in the global clinical impression of change measured by the CIBIC-Plus at 28 weeks (MD -0.30, 95% CI -0.58 to -0.02, p=0.04), in all cases the analysis was the ITT-LOCF population (Reisberg 2000). 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Main results We included 82 studies with 10,613 participants; 72 studies with 9783 participants provided extractable data. 5 key findings →
Design: meta-analysis Participants: 10,613 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease sufferers have been found to have a lack of the enzyme responsible for converting choline into acetylcholine within the brain. 5 key findings →
Design: randomized controlled trial Participants: 265 Evidence: high
Full summary, score breakdown and related studies → Original source
Accruing evidence from observational and epidemiological studies suggests an inverse relationship between dietary intake of omega 3 polyunsaturated fatty acid (PUFA) and risk of dementia. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
The statistical significance of these benefits could be overturned by data from two unpublished studies which are known to show no significant effect. 3. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Selection criteria All unconfounded trials specified as randomized in which treatment with piracetam was administered for more than a day and compared with placebo in patients with dementia of Alzheimer type, vascular dementia,or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling the criteria for dementia. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease sufferers have been found to have a lack of the enzyme responsible for converting choline into acetylcholine within the brain. 5 key findings →
Design: randomized controlled trial Participants: 265 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Studies conducted more than 20 years ago suggested that physostigmine could improve memory in people with or without dementia. 5 key findings →
Participants: 29 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There were no randomized trials found in the search. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The cross-over studies did not report results from the first phase. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Practitioners are keen to use snoezelen in dementia care, and some encouraging results have been documented in the area of promoting adaptive behaviours (e.g. The list of trials was compared with those identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There were no randomized trials found in the search. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nicotine is a cholinergic agonist that acts, not only post-synaptically, but also releases pre-synaptic acetylcholine, and in animal models has been shown to reverse spatial memory decline in rats with lesion in the medial septal nucleus and to show recovery on memory in aged monkeys. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 33,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 33,380 records, built mostly from automated pulls of Europe PMC (67.7% of the library) and OpenAlex (15.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,047 records (3.1% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated